Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 185

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Stimuli-responsive prodrug-based cancer nanomedicine

Open access
Xie, Angel, Hanif, Sumaira, Ouyang, Jiang, Tang, Zhongmin, Kong, Na, Kim, Na Yoon, Qi, Baowen, Patel, Dylan, Shi, Bingyang, Tao, Wei · 2020 · EBioMedicine

Abstract

The rapid development of nanotechnology results in the emergence of nanomedicines, but the effective delivery of drugs to tumor sites remains a great challenge. Prodrug-based cancer nanomedicines thus emerged due to their unique advantages, including high drug load efficiency, reduced side effects, efficient targeting, and real-time controllability. A distinctive characteristic of prodrug-based nanomedicines is that they need to be activated by a stimulus or multi-stimulus to produce an anti-tumor effect. A better understanding of various responsive approaches could allow researchers to perceive the mechanism of prodrug-based nanomedicines effectively and further optimize their design strategy. In this review, we highlight the stimuli-responsive pathway of prodrug-based nanomedicines and their anticancer applications. Furthermore, various types of prodrug-based nanomedicines, recent progress and prospects of stimuli-responsive prodrug-based nanomedicines and patient data in the clinical application are also summarized. Additionally, the current development and future challenges of prodrug-based nanomedicines are discussed. We expect that this review will be valuable for readers to gain a deeper understanding of the structure and development of prodrug-based cancer nanomedicines to design rational and effective drugs for clinical use.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ebiom.2020.102821

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 185

Metadata

Authors
Xie, A., Hanif, S., Ouyang, J., Tang, Z., Kong, N., Kim, N. Y., Qi, B., Patel, D., Shi, B., & Tao, W.
Venue
EBioMedicine
Publisher
Elsevier BV
Published
2020-06
Volume
56
Pages
102821
ISSN
2352-3964 (ISSN-L)
OpenAlex
W3032914086
Cited by
185
References
4
FWCI
5.83
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Stimuli-responsive prodrug-based cancer nanomedicine. https://app.cochat.ai/papers/10.1016/j.ebiom.2020.102821
The paper
Xie, A., Hanif, S., Ouyang, J., Tang, Z., Kong, N., Kim, N. Y., Qi, B., Patel, D., Shi, B., & Tao, W. (2020). Stimuli-responsive prodrug-based cancer nanomedicine. EBioMedicine. https://doi.org/10.1016/j.ebiom.2020.102821

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.